You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

MAXZIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Maxzide, and what generic alternatives are available?

Maxzide is a drug marketed by Aurobindo Pharma Usa and is included in one NDA.

The generic ingredient in MAXZIDE is hydrochlorothiazide; triamterene. There are thirty-two drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MAXZIDE?
  • What are the global sales for MAXZIDE?
  • What is Average Wholesale Price for MAXZIDE?
Drug patent expirations by year for MAXZIDE
Drug Prices for MAXZIDE

See drug prices for MAXZIDE

Drug Sales Revenue Trends for MAXZIDE

See drug sales revenues for MAXZIDE

Recent Clinical Trials for MAXZIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
VA Office of Research and Development
US Department of Veterans Affairs

See all MAXZIDE clinical trials

US Patents and Regulatory Information for MAXZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Usa MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Usa MAXZIDE-25 hydrochlorothiazide; triamterene TABLET;ORAL 019129-003 May 13, 1988 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MAXZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aurobindo Pharma Usa MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Usa MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MAXZIDE

See the table below for patents covering MAXZIDE around the world.

Country Patent Number Title Estimated Expiration
Philippines 21355 PHARMACEUTICAL COMBINATION COMPOSITION AND ASSOCIATED METHOD ⤷  Sign Up
Austria 51147 ⤷  Sign Up
Hong Kong 46285 COSMETIC COMPOSITIONS FOR THE TREATMENT OF DRY SKIN ⤷  Sign Up
Japan H0231053 ⤷  Sign Up
Philippines 20531 PHARMACEUTICAL COMBINATION COMPOSITION AND ASSOCIATED METHOD ⤷  Sign Up
Malaysia 8500566 COSMETIC COMPOSITIONS FOR THE TREATMENT OF DRY SKIN ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MAXZIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0480717 98C0025 Belgium ⤷  Sign Up PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0443983 C00443983/03 Switzerland ⤷  Sign Up PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0454511 SPC/GB99/008 United Kingdom ⤷  Sign Up PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0503785 CA 2011 00026 Denmark ⤷  Sign Up PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0502314 C300095 Netherlands ⤷  Sign Up PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
0502314 SPC/GB02/037 United Kingdom ⤷  Sign Up PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.